Literature DB >> 1507208

Synthesis and antiviral evaluation of N-carboxamidine-substituted analogues of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride.

B Gabrielsen1, M J Phelan, L Barthel-Rosa, C See, J W Huggins, D F Kefauver, T P Monath, M A Ussery, G N Chmurny, E M Schubert.   

Abstract

Ten, hitherto unreported, analogues of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride (2a, ribamidine) and methyl carboximidate 5 have been synthesized. These include the N-cyano (2b), N-alkyl (2c-e), N-amino acid (2f-h), N,N'-disubstituted (6, 7a,b), and the N-methylated carboxamide (1f) analogues of ribavirin. In addition, a new facile synthesis of carboxamidine 2a was also developed. All compounds were evaluated for biological activity against the following RNA viruses: Punta Toro (PT) and sandfly fever (SF) viruses (bunyaviruses); Japanese encephalitis (JE), yellow fever (YF), and dengue-4 viruses (flaviviruses); parainfluenza type 3 (PIV3), respiratory syncytial virus (RSV), and measles viruses (paramyxoviruses); influenza A and influenza B viruses (orthomyxoviruses); Venezuelan equine encephalomyelitis virus (VEE, alphavirus); human immunodeficiency virus type-1 (HIV-1, lentivirus); the DNA-containing vaccinia (VV) virus (poxvirus); and adeno type 5 (Ad5) viruses. All of the compounds except for 2b and 7a,b exhibited activity against the bunyaviruses such as that observed with 2a; however, higher IC50 values were generally observed. Glycine analogue 2f showed activity in PT-virus-infected mice in terms of increased survivors and decreased markers of viral pathogenicity. Carboxamidine 2a, carboximidate 5, and dimethyl amidine 6 exhibited activity against dengue type-4 virus. Monomethyl amidine 2c demonstrated activity against RSV, PIV3, and, to a lesser extent, influenza A and B. Activity of 2c generally required higher IC50 values than unsubstituted 2a. The latter exhibited hitherto unreported activity against RSV; therapeutic indices for 2a against RSV and PIV3 were greater than 64 and greater than 21. No substantial in vitro activity was observed for any of the compounds tested against Ad5, measles, JE, YF, VEE, or HIV-1. In addition, evidence is presented which argues in favor of a distinct antiviral mechanism of action for carboxamidines, e.g. 6, in contrast to a role as a carboxamide precursor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1507208     DOI: 10.1021/jm00095a020

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

Review 1.  Perspectives for the treatment of infections with Flaviviridae.

Authors:  P Leyssen; E De Clercq; J Neyts
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  (S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection.

Authors:  Blake P Moore; Dong Hoon Chung; Daljit S Matharu; Jennifer E Golden; Clinton Maddox; Lynn Rasmussen; James W Noah; Melinda I Sosa; Subramaniam Ananthan; Nichole A Tower; E Lucile White; Fuli Jia; Thomas E Prisinzano; Jeffrey Aubé; Colleen B Jonsson; William E Severson
Journal:  J Med Chem       Date:  2012-10-16       Impact factor: 7.446

3.  Potent non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex.

Authors:  Aiming Sun; Jeong-Joong Yoon; Yan Yin; Andrew Prussia; Yutao Yang; Jaeki Min; Richard K Plemper; James P Snyder
Journal:  J Med Chem       Date:  2008-06-05       Impact factor: 7.446

4.  Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex activity: Synthesis and in vitro evaluation.

Authors:  Aiming Sun; Nizal Chandrakumar; Jeong-Joong Yoon; Richard K Plemper; James P Snyder
Journal:  Bioorg Med Chem Lett       Date:  2007-07-04       Impact factor: 2.823

Review 5.  Cancer and virus leads by HTS, chemical design and SEA data mining.

Authors:  Pahk Thepchatri; Jaeki Min; Thota Ganesh; Yuhong Du; Iestyn Lewis; Serdar Kurtkaya; Andrew Prussia; Lian Li; Blossom Sneed; Richard K Plemper; Haian Fu; Dennis C Liotta; James P Snyder; Raymond Dingledine; Aiming Sun
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

6.  Therapeutic and prophylactic drugs to treat orthopoxvirus infections.

Authors:  Scott Parker; Lauren Handley; R Mark Buller
Journal:  Future Virol       Date:  2008-11       Impact factor: 1.831

7.  Structure-based and ligand-based virtual screening of novel methyltransferase inhibitors of the dengue virus.

Authors:  See Ven Lim; Mohd Basyaruddin A Rahman; Bimo A Tejo
Journal:  BMC Bioinformatics       Date:  2011-11-30       Impact factor: 3.169

Review 8.  Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses.

Authors:  Luděk Eyer; Radim Nencka; Erik de Clercq; Katherine Seley-Radtke; Daniel Růžek
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

9.  Structural effects on the phosphorylation of 3-substituted 1-beta-D-ribofuranosyl-1,2,4-triazoles by human adenosine kinase.

Authors:  Sidath C Kumarapperuma; Yanjie Sun; Marjan Jeselnik; Kiwon Chung; William B Parker; Colleen B Jonsson; Jeffrey B Arterburn
Journal:  Bioorg Med Chem Lett       Date:  2007-03-12       Impact factor: 2.823

10.  A cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virus.

Authors:  Dong-Hoon Chung; Blake P Moore; Daljit S Matharu; Jennifer E Golden; Clinton Maddox; Lynn Rasmussen; Melinda I Sosa; Subramaniam Ananthan; E Lucile White; Fuli Jia; Colleen B Jonsson; William E Severson
Journal:  Virol J       Date:  2013-01-10       Impact factor: 4.099

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.